Pharmaceutical contract research organisations M&A update
|
|
- Domenic Wiggins
- 7 years ago
- Views:
Transcription
1 Pharmaceutical contract research organisations M&A update Autumn % market growth driving M&A Contract research organisations (CROs) are becoming increasingly embedded in the drug development process. Industry research estimates that CRO revenues were worth US$22 billion in 2010 and are expected to reach US$33 billion by 2015 as the industry benefits from a long-term increase in spending on outsourced services and expansion into emerging markets. However, growth is occurring at the same time as structural change and this is creating volatility for market participants. Key findings from our research Globalisation and the move to strategic alliances favours specialists and those with scale. Emerging countries are now a core strategic market for pharmaceutical and biotech companies. At the same time, these companies are moving away from transactional relationships to strategic alliances. This favours CROs with scale, multiple capabilities and geographical reach. The survival of mid and small firms will depend on their ability to become market leaders within a particular geography or specialist research area. Large and mid-size CROs using M&A and joint ventures to meet sponsors needs. Companies are using joint ventures and acquisitions to infill therapeutic capabilities, extend geographic reach, especially in the high growth regions such as Latin America and China, and acquire different stage services in order to secure relationships with sponsors (including pharmaceutical and biotech companies). The evolving global marketplace for CROs is creating challenges and opportunities, with M&A activity driven by geographic expansion and private equity led consolidation Zachary Tsai, Catalyst Corporate Finance Private equity continues to grow platforms. Private equity have been long-term investors in the sector, attracted to the consolidation opportunities, ability to grow existing platforms and attractive returns. There have been a number of recent successful PE exits to strategic buyers including sales by Avista Capital and Welsh, Carson, Anderson & Stowe.
2 Pharmaceutical companies outsourcing non-core activities Industry Trends Increased outsourcing across the drug development lifecycle More stages of the drug development process are being outsourced as sponsors focus on reducing fixed costs, improving time to market and responding to increased global regulation (see Figure 1). Figure 1: R&D efficiency has declined significantly as regulation has become more stringent and biotechs have entered the market place No. of drugs per billion of USD R&D spending (inflation adjusted) The pressure on pharmaceutical companies to replace revenue due to impending patent protection losses is leading to a greater focus on late stage development, the lucrative generics market and finding novel revenuegeneration opportunities This is a positive environment for CROs which can expect to increase their share of R&D spend. As illustrated in Figure 2, the large majority of pharmaceutical companies expect to increase or maintain spending on outsourcing. Strategic alliances developing as sponsors rationalise drug portfolios Source: FDA Figure 2: Large majority of companies expect to increase or maintain outsourcing spend Predicted change in outsourced spending in 2013 Pharmaceutical companies have been rationalising their drug development portfolios to focus on a smaller number of core therapeutic areas. Mid and small CROs need to develop strong differentiators Consolidated portfolios mean sponsors are reducing their supplier base, preferring deep relationships with fewer CROs. Between 2010 and 2012, 13 large pharmaceutical companies had announced 22 major alliances. This includes Bayer HealthCare s long-term strategic partnership with Covance and Pfizer s two partner model, which cut its functional services providers from 17 to partnerships with just ICON and Parexel. This environment favours larger CROs with a multinational footprint and broad capabilities and expertise. The survival of mid and smaller firms will depend upon their ability to sell geographic expertise and demonstrate a specialist capability. Big pharma Top 10 biopharma Emerging biopharma Positively change Maintain current levels Decrease Source: Contract Pharma, May 2012 These pressures are driving M&A activity. Larger CROs which need to gain a particular strategic advantage are attracted to specialist firms. For example, US-based CRO QPS acquired a majority stake in Austrian JSW Life Sciences, a full service CRO specialising in central nervous system diseases which has operations in Central and Eastern Europe. Large and mid-tier CROs are using acquisitions to extend their geographic and therapeutic reach, as well as broadening their offering. 2
3 US-based INC Research acquired Australian Trident Clinical Research to gain expertise in Australia, New Zealand and India; regions which are important for cost-effective local and global drug development programmes. INC s second acquisition in 2011 was the million purchase of US CRO Kendle. This strengthened INC s ability to manage large scale global trials by significantly expanding its therapeutic expertise and geographic reach (see Figure 5). CROs accessing emerging markets increasing share of global outsourcing revenues Pharmaceutical companies are attracted to the growing international market for drugs led by consumer demand and increasing national health budgets in emerging markets (see Figure 3). This is creating demand for locally based CROs expertise and knowledge of unfamiliar regulatory regimes. Emerging markets are challenging to penetrate organically and large Western CROs are using partnerships with local firms to ensure they can meet their local and global clients objectives. For example, US Quintiles is investing US$14 million in a regional Figure 3: Emerging markets are increasing healthcare spending significantly Growth in healthcare spending per capita The two-partner model will simplify our processes, significantly reducing the number of external service providers we use for clinical trial execution, and clarify accountability in risk and quality management. Dr. John Hubbard, Senior Vice President Development Operations, Pfizer Source: Pfizer press release, 26 May 2011, headquarters for China and a significant expansion of its local laboratory testing capabilities through a joint venture with the Shanghai Clinical Research Centre. The fragmented nature of these markets means careful selection of the right partner or platform is key. Increasingly, large CROs are establishing market leaders through buy and build strategies. For example, ICON (UK) acquired BeijingWits Medical Consulting, a full-service Chinese CRO. PPD (US) gained additional capacity and expertise in China and the wider Asia Pacific region via its acquisition of Excel PharmaStudies, and Chiltern (UK) acquired Brazilian CRO Vigiun to deepen its capabilities in the strategically important Latin America region. Emerging markets strategically important CROs using joint ventures and acquisitions to access high growth regions % China Brazil India 120 US 100 UK Source: World Bank, Healthcare spending per capita USD (sum of public and private spending) In the evolving global market, scale is a key competitive advantage to developing strategic relationships with our clients. Paul Meister, Chief executive officer, inventiv Health Source: inventiv Health press release, 17 May 2011, 3
4 Pharmaceutical companies focusing on late-stage development A shift to late stage investment The pressure on sponsors to improve revenues in the short and medium term is forcing them to prioritise investment in lower risk and lower cost late-stage development. Faster growth in drug candidates in stage III is delivering short term volumes to CROs providing later stage services (see Figure 4). Figure 4: Number of drugs pushed through to stage lll has increased 26% since 2009, but growth in new drugs added to stages l and ll have tapered off Growth in number of drug candidates at each development stage since January 2009 The longer term impact of this is a decline in novel therapeutics in the development funnel as drug discovery activities are neglected in favour of faster developments. This will lead to a period of fierce competition and reduced demand in the CRO market, a catalyst for consolidation and diversification until sponsors shift their attention back to refilling the earlier stage pipeline. 135% 130% 125% 120% 115% 110% 105% 100% 95% 90% Jan 09 Apr 09 Jul 09 Oct 09 Jan 10 Apr 10 Jul 10 Pre-clinical Phase ll compounds Source: William Blair Oct 10 Jan 11 Apr 11 Jul 11 Oct 11 Jan 12 Apr 12 Jul 12 Phase l compounds Phase lll compounds Oct 12 Figure 5: In focus: INC Research INC Research is a top-tier global CRO providing the full range of Phase I to IV clinical development services. Their strategy includes international organic growth, acquisitions and securing private equity backing. Acquisition strategy Increasing access to emerging markets In 2011, INC acquired Australian Trident Clinical Research to gain expertise in Australia, New Zealand and India, regions which are important for costeffective local and global drug development programmes. Increasing therapeutic and trial expertise The acquisitions of NDDO Oncology (2005) and Pharmaceutical Resource Corporation (2006) gave INC expertise in anticancer drug development, late phase study experience and strong pharmacovigilance and drug safety expertise. Adding scale Earlier acquisitions include European CRO Vujaklija, one of the first CROs in Central and Eastern Europe (2002), and the Phase II-IV operations (Global Clinical Development) of MDS Pharma Services in 2009 for 30.4 million. This extended INC s presence in emerging markets and deepened expertise in vaccine, respiratory, cardiovascular and endocrinology clinical research. A 2007 joint venture with GVK Biosciences established a platform for INC to run full service Phase I-IV clinical trials in India for its global clients. The million purchase of publicly listed US CRO Kendle in 2011 strengthened INC s ability to manage large scale global trials by significantly expanding its therapeutic expertise and geographic reach and moved INC in to the top tier of CROs. Ownership In 2010, Avista Capital Partners and Ontario Teachers Pension Plan acquired INC from its backers, an investor group led by Crosspoint Venture Partners and Adams Street Partners, for around 382 million. 4
5 Valuations Using valuations of the leading CROs as a proxy for sentiment towards the whole sector, Figure 6 shows EV/EBITDA has averaged 9.4x since global stock markets bottomed in March 2009, consistently outperforming the broader pharmaceutical sector, albeit with greater volatility. Figure 6: Since stock markets bottomed in March 2009, EV/EBITDA of leading CROs has risen from 6.6x to 10.2x EV/EBITDA of leading CROs and Big Pharma 12.0x 11.0x 10.0x 9.0x 8.0x 7.0x 6.0x 5.0x 4.0x Mar 2009 May 2009 Jul 2009 Sep 2009 Nov 2009 Jan 2010 Mar 2010 May 2010 Jul 2010 Sep 2010 Nov 2010 Jan 2011 Mar 2011 May 2011 Jul 2011 Sep 2011 Nov 2011 Jan 2012 Mar 2012 May 2012 Jul 2012 Sep 2012 Leading CROs 10.2x Big pharma 8.4x Figure 7: Selected acquisitions of publicly quoted CROs acquired by private equity Target Acquirer Date Deal value ( m) PPD The Carlyle Group and Hellman & Friedman Oct ,502.9 Kendle International INC Research (Avista and May Ontario Teachers ) Theorem Clinical Research Nautic Partners Apr-2011 nd (formerly Omnicare CRO) inventiv Health Thomas H. Lee Partners May PharmaNet JLL Partners Mar-2009 nd PRA International Genstar Capital Jul Synexus Lyceum Capital Nov Source: Capital IQ, Catalyst Corporate Finance Source: Capital IQ Financial buyers facilitating consolidation A number of the largest CROs are private equity backed including Quintiles, PPD, INC Research, inventiv Health, QPS, Medpace and PRA International. Recent M&A activity has been characterised by add-on acquisitions as firms continue to invest in existing platforms. Thomas H. Lee-backed inventiv Health has been a serial acquirer in the sector. Acquisitions include PharmaNet Development Group which helped the company extend its geographical reach and enhance its early and late stage clinical development capabilities. PharmaNet was owned by JLL Partners and the sale represented a 5.9x multiple on their investment. Exit activity has included sales to strategic buyers. For example, Avista Capital s 227 million sale of BioReliance to Sigma-Aldrich, acquired in 2007 for 130 million, and the 249 million sale of Aptuit s Clinical Trials Supply business by Welsh, Carson, Anderson & Stowe to Catalent Pharma Solutions. Whilst IPOs are likely to be an option for the largest CROs such as Quintiles, the largest deal in the sector over the last few years has been the take-private transaction of PPD by Carlyle and Hellman & Friedman for 2.5 billion or around 10x EBITDA. This transaction followed a number of other PE acquisitions of publicly traded CROs including INC s acquisition of Kendle and Nautic s acquisition of Omnicare (now Theorem Clinical Research), see Figure 7. Private equity have a successful record 5
6 Expect further consolidation Outlook and prospects for M&A The pressures facing pharmaceutical companies mean that demand for outsourced R&D will increase, but the challenges facing CROs discussed above mean that the sector will continue to be volatile. In particular, we expect to see: CROs which lack a distinctive proposition will be increasingly vulnerable. Those CROs which do not have a particular specialism or lack breadth (geographically or therapeutic) will struggle to compete against fullservice global CROs and genuine specialists. Large and mid-tier CROs continuing to build scale and expertise. Under pressure to offer a comprehensive global offering, large and mid tier CROs will continue to build scale by expanding geographically, particularly into emerging markets, and developing broad service expertise. M&A will be a key part of this strategy as companies look for local specialists, smaller CROs with niche capabilities, or opportunities to consolidate market share in mature and lower growth markets. Ongoing private equity investment. PE will continue to be active, facilitating consolidation, strategic bolt-on acquisitions and investment in platforms. Contact us Catalyst Corporate Finance has an experienced team of healthcare experts. If you would like to discuss this report in more detail, contact us on +44 (0) Andy Currie, Managing Partner Andy is Managing Partner at Catalyst. His chief responsibilities include advising on MBOs, fund raising, company acquisitions and disposals. Andy has transacted across multiple sectors including the healthcare sector where completed deals include the sale of ScriptSwitch to UnitedHealth Group Inc. Justin Crowther, Director Justin is a Director at Catalyst and has over ten years corporate finance experience. His main responsibilities include advising on MBOs, fund raising, company acquisitions and disposals. Justin leads our global healthcare sector team with completed deals including the sale of Solor Care Group to Voyage Holdings Limited. Zachary Tsai, Principal Zac is a Principal at Catalyst and has over six years experience in M&A. His main responsibilities include advising on MBOs, fund raising, company acquisitions and disposals. He leads our focus on the UK and international pharmaceuticals market. Zac has completed a number of deals including the sale of UL Medicines to Quantum Pharmaceutical. James Knott, Executive James is an Executive at Catalyst where his main responsibilities include advising on MBOs, fund raising, company acquisitions and disposals. James specialises in the medical devices sector and has been involved in a number of deals including the sale of FirstAssist Services to Capita Group Plc. 6
7 Figure 8: Selected recent M&A transactions Date Target Country Description Acquiror Country Value ( m) Sep-12 Paragon Biomedical Inc USA Operate a full-service clinical research organisation Clinipace Worldwide Inc USA nd Sep-12 Vitalea Science Inc USA Provides contract research services in the pharmaceutical field Eckert & Ziegler AG Germany nd Aug-12 Expression Analysis Inc USA Provides genomics testing and analysis Quintiles Transnational Corp USA nd Aug-12 JSW Life Sciences GmbH Austria Provides preclinical and clinical Phase II IV drug development services QPS Holdings, LLC USA nd May-12 Centrum Medyczne Osteomed Poland Provides clinical research services Synexus Ltd UK nd Feb-12 Aptuit s Clinical Trial USA Provides clinical supplies services Catalent Pharma Solutions USA 249 Supplies business Feb-12 PriceSpective LLC USA Management consulting company for biopharmaceutical and medical technology assets ICON plc UK nd Jan-12 BioReliance USA Provides testing and manufacturing services Sigma-Aldrich USA 227 Dec-11 BeijingWits Medical Consulting China Provides clinical research services ICON plc UK nd Oct-11 Advion BioServices Inc USA Provides bioanalytical, immunoassay, sample management, Quintiles Transnational Corp USA nd metabolism, biomarker, and discovery services Oct-11 VCG & Associates Inc USA Provides pharmaceutical consulting and account Quintiles Transnational Corp USA nd management implementation outsourcing services Oct-11 PPD Inc USA Provides discovery and development services and products Private Group led by The Carlyle Group USA 2,502.9 and Hellman & Friedman Jun-11 Trident Clinical Research Australia Provides contract clinical research services INC Research Inc USA nd Pty Ltd May-11 PharmaNet Development Group Inc USA Provides contract research services inventiv Health Inc USA nd May-11 Kendle International Inc USA Provides contract research and development services INC Research Inc USA Mar-11 Phlexglobal Ltd UK Provides contract research services Private Group led by Inflexion Private Equity UK nd Feb-11 Dec-10 Bioserve Clinical Research Limited Research Pharmaceutical Services Inc India Provides contract research services QPS Holdings, LLC USA 3.7 USA Provides comprehensive global Phase 1-4 clinical development solutions Aug-10 INC Research Inc USA Provides customised programmes in areas including paediatric and womens health trials Private Group led by Warburg Pincus LLC USA Private Group led by Avista Capital Partners and Ontario Teachers Pension Plan USA Aug-10 ClinTec International Ltd UK Provides clinical research support services Elephant Capital Plc UK 8.4 Jul-10 Xendo Drug Development BV Netherlands Provides contract research services QPS Holdings, LLC USA nd Jan-10 Chiltern International UK Provides contract research and development services Greenhill Capital Partners USA nd Holdings Ltd Jan-10 Medical Consulting Dr Germany Provides regulatory and pharmacovigilance services Medpace Inc USA nd Schlichtiger GmbH Dec-09 ClinPharm International GmbH Germany Provides contract pharmaceutical and biotechnical Synexus Clinical Research Ltd UK nd research services Nov-09 Excel PharmaStudies Inc China Provides clinical research, registration, biometrics, and training and consultation services PPD Inc USA nd Sep-09 Paragon Biomedical Inc USA Full-service clinical research organisation Clinipace Worldwide Inc USA nd Jun-09 Phase II-IV Operations of MDS Pharma Services Inc USA Provides research services and undertakes clinical trials INC Research Inc USA 30.4 May-09 Farma Resa Imp Srl Italy Provides clinical research services Hyperphar Group SpA Italy 1.4 Apr-09 Vigiun Brazil Provides clinical research services Chiltern International Holdings Ltd UK nd Apr-09 Piedmont Research Center LLC USA Provides preclinical discovery services focused on efficacy studies in oncology and other therapeutic areas Charles River Laboratories International Inc USA 31.9 Mar-09 Swiss Pharma Contract Ltd Switzerland Provides clinical pharmacology and research services Covance Inc USA nd Feb-09 AbCRO Inc Bulgaria Provides contract research services in Central and Eastern Europe Sep-08 Molecular Imaging Research Inc USA Provides contract research services specialising in anti-cancer and anti-inflammtory therapeutic agents Mar-08 Premier Research Group Plc UK Provides clinical trial management and informatics capabilities PPD Inc USA nd Charles River Laboratories Inc USA 6.9 Management buy-out backed by ECI Partners and Indigo Capital UK 88.4 Feb-08 InnoPharm Ltd Russia Provides Phase II-IV clinical trials support PPD Inc USA nd Jan-08 AppTec Laboratory Services USA Provider of contract research and development services WuXi PharmaTech China 81.9 Jan-08 Hyperphar Group SpA, Italy Italy Provides contract research to the pharmaceutical, biotechnology and healthcare industries Pierrel SpA, Italy Italy 6.4 Source: Catalyst Corporate Finance 7
8 Recent Catalyst Corporate Finance healthcare deals include Lead adviser on sale to Lead adviser on sale to Lead adviser on sale to Catalyst Corporate Finance Award-winning international corporate finance advice Catalyst advises management teams, private shareholders and corporates on: Buying businesses (MBOs/MBIs/BIMBOs) Selling businesses Searching for businesses to acquire, both in the UK and overseas Investment opportunities for private equity firms Maximising shareholder value This is all we do and all we want to do. Mid Market Adviser of the Year 2011 International experience Through our international partnership, Mergers Alliance, Catalyst Corporate Finance provides: Access to overseas buyers Local knowledge of M&A culture and tactics International M&A Research Identifying targets overseas and executing acquisitions London: 5th Floor, Grosvenor Gardens London SW1W 0DH Tel: +44 (0) Birmingham: 9th Floor, Bank House, 8 Cherry Street Birmingham B2 5AL Tel: +44 (0) Nottingham: 21 The Triangle, ng 2 Business Park Nottingham NG2 1AE Tel: +44 (0) Catalyst Corporate Finance LLP is a limited liability partnership registered in England & Wales (registered number OC306421) Registered Office: Bank House, 8 Cherry Street, Birmingham, B2 5AL Catalyst Corporate Finance LLP is authorised and regulated by the Financial Services Authority (number )
CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW
CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW April 2014 Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams
More informationThe Top 10 Contract Research Organizations
OUTSOURCING The Top 10 Contract Research Organizations Positioning, performance and SWOT analyses Table of Contents Copyright 2009 Business Insights Ltd This Management Report is published by Business
More informationIn-depth analysis of the report is based on propriety databases, primary and secondary research and inhouse analysis by a team of experts.
Brochure More information from http://www.researchandmarkets.com/reports/1882193/ Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising
More informationGlobal Contract Research Organization (CRO) Industry: Overview and Trends, 2008
A Service of Indigo Research A Cipher www.indigoresearch.com Global CRO Market 2005- $15 Billion Global Contract Research Organization (CRO) Industry: Overview and Trends, 2008 Published April 2008 CRO
More informationAPAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015
APAC CRO Market A deep dive into the trends transforming APAC CRO industry June 2015 Table of Contents Section Slide Numbers Executive Summary 10 Key Findings 11 Total CRO Market Size By Stages of Clinical
More informationPharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595
Transparency Market Research Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample Published Date:
More informationThe Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry
Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge
More informationSector update Consultancy services Autumn 2014
Bs Sector update Consultancy services Autumn 2014 Business Services Consultancy M&A driven by increasingly sophisticated client demands The global economic recovery and a progressively complex multi-national
More informationAPAC Contract Research Organisation (CRO) Market
Brochure More information from http://www.researchandmarkets.com/reports/3308444/ APAC Contract Research Organisation (CRO) Market Description: The research service presents an overview and analysis of
More informationBrochure More information from http://www.researchandmarkets.com/reports/2011199/
Brochure More information from http://www.researchandmarkets.com/reports/2011199/ Healthcare BPO Market - Payer (Claims Processing), Provider (Medical Billing & Coding) & Pharmaceutical (Clinical Trial
More informationBayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to
More informationLife Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com
Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationAT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More informationHow does a venture capitalist appraise investment opportunities?
1 How does a venture capitalist appraise investment opportunities? Michael Queen - Finance Director, 3i Group plc A presentation to: 23 Pensions Convention 2 June 23 A How presentation does a venture to:
More informationGlobal Small Cap Investing: Unconstrained Opportunities
May 2013 Global Small Cap Investing: Unconstrained Opportunities Andrew G. Flynn, Partner, CFA Globalization: What Does it Mean? International integration arising from the interchange of world views, products,
More informationCreative financing: Private equity in life sciences
: Private equity in life sciences The Colonnade Hotel, Boston, MA October 28, 2008 Industry trends and implications 2 Setting the Stage Overall trends Aging population Emerging market opportunities - access
More informationMarket Insights Life Sciences
Market Insights Life Sciences Key Facts Scotland hosts the UK s second largest life sciences cluster and one of the most sizeable in Europe. The life sciences sector contributes 3.1 billion turnover and
More informationPCPIQ1 Private Company Price Index. Spotlight on Software & IT Services
2014 PCPIQ1 Private Company Price Index Spotlight on Software & IT Services 2 PCPI/PEPI IS IT ALL BAD NEWS? 2013 ended on a high: deals in Q4 2013 were up by 5.4% yearon-year, and the Private Company Price
More informationHow international expansion is a driver of performance for insurers in uncertain times
How international expansion is a driver of performance for insurers in uncertain times Accenture Global Multi-Country Operating Model Survey May 2009 Copyright 2009 Accenture. All rights reserved. Accenture,
More informationTime and Cost Reduction in Clinical Trials- Outsourcing and IT to Optimize Patient Recruitment, Logistics, Data and Site Management
Time and Cost Reduction in Clinical Trials- Outsourcing and IT to Optimize Patient Recruitment, Logistics, Data and Site Reference Code: GBIHC088MR Publication Date: June 2011 Biopharmaceutical companies
More informationCORPORATE AND SECURITIES PARIS LLP
CORPORATE AND SECURITIES PARIS LLP ddefinitive ADVICE PRACTICAL GUIDANCE POWERFUL ADVOCACY A dedicated team of more than 25 corporate and securities lawyers in Paris who advise French and foreign multinational
More informationDeutsche Global Infrastructure Fund (TOLLX)
Global Infrastructure Fund (TOLLX) A step beyond MLPs Important risk information Any fund that concentrates in a particular segment of the market will generally be more volatile than a fund that invests
More informationBioTuesday Introduction to Kendle. Philippe Moreau, CRA Manager
BioTuesday Introduction to Kendle Philippe Moreau, CRA Manager March 1, 2011 Overview Top-tier CRO uniquely positioned to deliver Phases I-IV 30-year track record of delivering on client expectations Partners
More informationPrivate Equity investment in Recruitment companies - what are we looking for? Chris Harper Managing Director Baird Capital
Private Equity investment in Recruitment companies - what are we looking for? Chris Harper Managing Director Baird Capital About The Presenter Chris Harper 25 years within private equity Managing Director
More informationStandard Life Investments strengthens strategic position through acquisition of Ignis Asset Management
For release at 07:00 (UK time) 26 March 2014 Standard Life Investments strengthens strategic position through acquisition of Ignis Asset Management Acquisition of Ignis Asset Management by Standard Life
More informationInvestment Strategy for Pensions Actuaries A Multi Asset Class Approach
Investment Strategy for Pensions Actuaries A Multi Asset Class Approach 16 January 2007 Representing Schroders: Neil Walton Head of Strategic Solutions Tel: 020 7658 2486 Email: Neil.Walton@Schroders.com
More informationSpring 2013. From Our CEO. Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai
From Our CEO Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai Featured Story WuXi and PRA Form Joint Venture to Offer Clinical Research Services
More informationDecember 2012. Emerging Markets Small Cap: The Undiscovered Frontier
December 212 Emerging Markets Small Cap: The Undiscovered Frontier 1 23481 The EM Small Cap Opportunity Set Global Small Cap Universe Number of Companies Emerging markets small cap comprises approximately
More informationAttractive near-shore M&A opportunities in added-value BPO categories
Global Business Process Outsourcing M&A update Autumn 2014 Attractive near-shore M&A opportunities in added-value BPO categories The global business process outsourcing (BPO) industry is changing, from
More informationMergers and Acquisitions Trends in the Global Property and Casualty Insurance Industry
Mergers and Acquisitions Trends in the Global Property and Casualty Insurance Industry Improving Industry Health to Bolster Global Merger Activity in 2014 NC3B-F1 January 2013 Contents Section Slide Number
More informationAn Overview of Private Equity
An Overview of Private Equity September 29, 2014 Private Equity Panel Moderator Les Alexander, Partner, Jefferson Capital Partners Panelists Mark Jones, Partner, River Associates Investments Gretchen Perkins,
More information2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q
2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationUS companies leading surge in M&A
The Deloitte M&A Index Q3 215 US companies leading surge in M&A Key points The first half of 215 has emerged as one of the strongest for M&A, with more than $1.8 trillion worth of deals announced globally,
More informationHSBC Holdings plc and HSBC Bank Canada Presentation to Fixed Income Investors. September 2013
Holdings plc and Bank Canada Presentation to Fixed Income Investors September 2013 Forward-looking statements This presentation, including the accompanying slides and subsequent discussion, contains certain
More informationDisclaimer: Forward Looking Statements
Disclaimer: Forward Looking Statements This presentation/announcement may contain forward looking statements with projections regarding, among other things, the Company s strategy, revenues, earnings,
More informationINDEX SERIES FTSE PUBLICATIONS. FTSE ETF Issuer Services.
INDEX SERIES FTSE PUBLICATIONS FTSE ETF Issuer Services. BEIJING BOSTON DUBAI HONG KONG LONDON MILAN MUMBAI NEW YORK PARIS SAN FRANCISCO SHANGHAI SYDNEY TOKYO FTSE FTSE Group ( FTSE ) is a world-leader
More informationTim Howkins, CEO. Steve Clutton, Finance Director
Tim Howkins, CEO Steve Clutton, Finance Director Highlights Revenue Revenue up 36% Earnings per share up 33% All parts of business contributed to growth Benefits of increased IT spend Proposed final dividend
More informationResults presentation Six Months Ended 30 November 2006
Results presentation Six Months Ended 30 November 2006 Tim Howkins, CEO Steve Clutton, Finance Director Introduction Turnover up 44% Highlights Earnings per share up 43% All parts of business contributed
More informationMembership 54% 18% 28% Bank Captive Independent & Mult Line
Membership Bank Captive Independent & Mult Line 54% 18% 28% Business Fixed Investment & Equipment Financing Volume ($ Billions) New Business by Equipment Type Source: 2012 SEFA $14.0 $12.0 $10.0 $8.0 $6.0
More informationGlobal Equity Trading Volumes Surge 36% in 1 st half 2015 driven by Mainland China
Global Equity Trading Volumes Surge 36% in 1 st half 215 driven by Mainland China Global Equity Trading Volumes Ex Mainland China Up 5% Mainland China Share Trading Vols Rise 166% in H1 215 vs H2 214 The
More informationSVIIT Interim results for six months to 30 June 2003
SVIIT Interim results for six months to 30 June 2003 Dec-02 Apr-03 Aug-03 Aug-02 Apr-02 Dec-01 SVIIT NAV Growth vs. Peer Group 250 200 150 SVIIT NAV Pantheon NAV Candover NAV Electra NAV Graphite NAV 3i
More informationStabilus at a glance. April 2014
Stabilus at a glance April 2014 Stabilus Overview Sales: 460mm Employees: ~4,000 Plants: 11 Sales by region 1 : Europe: 53% NAFTA: 34% Asia / RoW: 13% Automotive Industrial Gas springs Powerise Capital
More informationExtract of article published in International HR Adviser magazine 2013. The role of HR in global mobility
Extract of article published in International HR Adviser magazine 2013 The role of HR in global mobility Increasingly the regional HR director for Asia Pacific for many large multinationals will be based
More informationOpen Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum
Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities
More informationFor more information and analysis, please see the factsheet that follows.
Press Release 5 th January 215 214 Equity-Backed Buyout Deals and Exits Reach Highest Levels Since the Global Financial Crisis The total value of exits from private equity-backed portfolio companies throughout
More informationSTRATEGY UPDATE 2 MARCH 2016
STRATEGY UPDATE 2 MARCH 2016 Portfolio Focus on Attractive Growth and Margin Opportunities André Lacroix, CEO Intertek Group plc, is today announcing a strategic update outlining the Group s plan to deliver
More informationCOVANCE INC. NYSE: CVD
COVANCE INC. NYSE: CVD JOE HERRING CHAIRMAN AND CEO June 3, 2014 Safe Harbor Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings,
More informationAPRIL 2015. Economic Impact of AIM
APRIL 2015 Economic Impact of AIM Foreword AIM, which is 20 years old this year, has weathered several economic storms over the past two decades, but has remained true to its core purpose of providing
More informationOur business, vision and what we do
ADVERTISEMENT: This is an advertisement and not a prospectus. In the event that CMC Markets undertakes a flotation, a prospectus will be produced and made available on www.cmcmarkets.com/group/ipo. Any
More informationStandard Life plc Half year results 2015 4 August 2015
Standard Life plc Half year results 2015 4 August 2015 Focus on fee business driving growth and performance Fee based revenue, including Ignis, up 17% to 761m with 95% of income now fee based Assets under
More informationThe rise of the cross-border transaction. Grant Thornton International Business Report 2013
The rise of the cross-border transaction Grant Thornton International Business Report 2013 Foreword MIKE HUGHES GLOBAL SERVICE LINE LEADER MERGERS & ACQUISITIONS GRANT THORNTON INTERNATIONAL LTD When reflecting
More informationMedical Equipment Monthly Deals Analysis: January 2015- M&A and Investment Trends
Medical Equipment Monthly Deals Analysis: January 2015- M&A and Investment Trends Reference Code: GDME0470MD Publication Date: March 2015 Independent Medical Equipment Research M&A Trends and Analysis
More informationClinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.
Clinical Trial Trends Outline Complexity for Supply Chain Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.com 29 May 2013 Biotechnology Sales on the Rise Source: EvaluatePharma
More informationSupport Services insights from Clearwater April 2013. clearthought. The recruitment industry prepares for a new race that will drive M&A
Support Services insights rom Clearwater April 03 clearthought Ready, Set, Go! The recruitment industry prepares or a new race that will drive M&A Introduction The race to the top is hotting up in the
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationGlobal Invacom Group Limited Completing The Picture. SGX Connect Seminar 5 March 2015
Global Invacom Group Limited Completing The Picture SGX Connect Seminar 5 March 2015 Presentation Outline 1 Global Invacom Overview 2 Recent Corporate Developments 3 FY2014 Financial Highlights 4 Strategy,
More informationGLOBAL DATA CENTER INVESTMENT 2013
2013 CENSUS REPORT: Global Data Center Investment 2013 GLOBAL DATA CENTER INVESTMENT 2013 2013 - Healthy Growth in Data Center Investment Globally Globally, the data center industry has continued to maintain
More informationInvesting in Bonds challenges and opportunities in 2015
For Financial Brokers and Advisors Only Investing in Bonds challenges and opportunities in 2015 March 2015 Andy Ivory-Corr, QFA, Grad Dip, CFP Head of Investments New Ireland Assurance What exactly is
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationPEDIATRIC MEDICINES: GLOBAL MARKETS
PEDIATRIC MEDICINES: GLOBAL MARKETS PHM170A October 2014 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-56965-971-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationfor Analysing Listed Private Equity Companies
8 Steps for Analysing Listed Private Equity Companies Important Notice This document is for information only and does not constitute a recommendation or solicitation to subscribe or purchase any products.
More informationZ E N T I VA AT G L A N C E. We a i m t o b e y o u r va l u e d ge n e r i c s partner
Z E N T I VA AT G L A N C E We a i m t o b e y o u r va l u e d ge n e r i c s partner Poland Czech Republic Germany United Kingdom France Portugal Switzerland Italy Slovenia Estonia Latvia Lithuania Slovakia
More informationJoin our scientific talent community
Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into
More informationPhilips Healthcare overview. Steve Rusckowski CEO Philips Healthcare
Philips Healthcare overview Steve Rusckowski CEO Philips Healthcare 1 Executive summary Exited 2010 with solid growth and strengthened operational performance as promised Grew faster than our markets,
More informationshutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success
shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success Proven success and contacts. Not just talk. TCG is a
More informationVinaCapital Investor Conference 2010 Vietnam Funds. Hiroshi Funaki Head of Research LCF Edmond de Rothschild Securities, October 2010
VinaCapital Investor Conference 2010 Vietnam Funds Hiroshi Funaki Head of Research LCF Edmond de Rothschild Securities, October 2010 LCF Edmond de Rothschild Securities Specialist Emerging Markets Funds
More informationImportant Information.
JUNE 2011 KESTREL INHERITANCE TAX SOLUTION Many individuals are concerned about the impact that inheritance tax (IHT) will have on the value of their estates and are looking for solutions that will minimise
More informationEEA Life Settlements Fund
EEA Life Settlements Fund An Absolute Return, Historically Uncorrelated Investment Solution This document is being directed only at persons who are professional clients or eligible counterparties for the
More informationCorporate Presentation. CMIC Co., Ltd. Chairman and CEO Kazuo Nakamura
Corporate Presentation CMIC Co., Ltd. Chairman and CEO Kazuo Nakamura Current Topics Dec.10 2007 Eisai announced its acquisition of US-based MGI Pharma Feb 4,2008 Amgen and Takeda announced their exclusive
More informationBest Connected Software from Ireland
Best Connected Software from Ireland A strategy for development of the indigenous software industry 2009-2013 Irish Software a Modern Success Story Over the past thirty years, Ireland has built an international
More informationGeneral Legal Service Provider Information Form
General Legal Service Provider Information Form General information Name of Organisation LK Shields Solicitors Contact information Head of Organisation: Hugh Garvey (Managing Partner) Name: LK Shields
More informationWhite Paper CLINICAL RESEARCH IN POLAND AN INTRODUCTION
White Paper CLINICAL RESEARCH IN POLAND AN INTRODUCTION Table of Contents 1. Healthcare Landscape in Poland... 3 2. Clinical Research Activity in Poland... 3 3. References... 6 4. About the Author... 6
More informationAsian Stock Markets in 2015:
Asian Stock Markets in 2015: Expected trends and the role of Asian Funds Passports Dr. Andrew Freris CEO, Ecognosis Advisory Ltd March 2015 1 Summary, Part I The Asian markets which outperformed in 2014,
More informationState of the Life Sciences Mergers and Acquisitions Market
State of the Life Sciences Mergers and Acquisitions Market Brian Miller, Managing Partner and Co-Founder, Linden Partners Rich Fante, RF Consulting LLC, Formerly with AstraZeneca Americas Mark Nicholson,
More informationHealth Care Worldwide. Citi - European Credit Conference September 24, 2015 - London
Health Care Worldwide Citi - European Credit Conference September 24, 2015 - London Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties.
More informationQuest for Growth Results for Q3, January-March 2003
Quest for Growth Results for Q3, January-March 2003 1 Jan Keuppens joins Quest Management Investment Manager Quoted Portfolio of Quest for Growth Former technology analyst with AXA Investment Managers,
More informationTaking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset
Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened
More informationMETLIFE EMPLOYEE BENEFITS PROVIDING CERTAINTY FOR EMPLOYEES
METLIFE EMPLOYEE BENEFITS PROVIDING CERTAINTY FOR EMPLOYEES 3 IN AN UNCERTAIN ECONOMIC ENVIRONMENT, PROVIDING CERTAINTY FOR EMPLOYEES IS ESSENTIAL Employees are an organisation s most valuable asset.
More informationORTHOPEDIC INDUSTRY OVERVIEW
ORTHOPEDIC INDUSTRY OVERVIEW May 2014 Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams & Co. Ltd, which is authorised
More informationQ1 Trading Update, FY 2011
ARYZTA AG Q1 Trading Update, FY 2011 29 November 2010 Forward Looking Statement This document contains forward looking statements which reflect management s current views and estimates. The forward looking
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationA PROVEN APPROACH to ACCELERATED CLINICAL DEVELOPMENT
Accelovance 2275 Research Boulevard, Suite 700 Rockville, MD 20850, United States Phone: +1.240.238.4900 Fax: +1.240.238.4901 Internet: www.accelovance.com email: gsmith@accelovance.com Contact Person:
More informationHalf Year Financial Results
16 August 2012 Manager ASX Market Announcements Australian Securities Exchange Level 4, 20 Bridge Street Sydney NSW 2000 Manager Market Information Services Section New Zealand Stock Exchange Level 24,
More informationMalignant Pleural Mesothelioma - Pipeline Review, H2 2014
Brochure More information from http://www.researchandmarkets.com/reports/2904677/ Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Pleural Mesothelioma - Pipeline Review,
More informationCorporate Presentation. Southern Cone / Andean CEO Conference May, 2012
Corporate Presentation Southern Cone / Andean CEO Conference May, 2012 Our Company 2 Company overview Largest Latin American IT Services provider and an undisputed leader in systems integration, support
More informationHAS THE INSURANCE BROKERAGE MARKET PEAKED?
CORPORATE FINANCE TRANSACTION ADVISORY SERVICES HAS THE INSURANCE BROKERAGE MARKET PEAKED? by Arik Rashkes and Richard Forgione 2 OVERVIEW OF ECONOMIC CONDITIONS Improving economic conditions and asset
More informationQ1 14 Global IPO update. January March 2014
Q1 14 Global IPO update January March 214 Table of contents Section Content Slides 1 214 January March* highlights 4 7 2 Global IPO activity trends Global analysis Regional analysis Industry analysis Stock
More informationJ.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles
J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
More informationApples Review of 2012/13 season Prognosfruit - Congress 2013 Helwig Schwartau, AMI
Apples Review of 2012/13 season Prognosfruit - Congress 2013 Helwig Schwartau, AMI Market balance for table apples in EU-27 1.000 tons 2009/10 2010/11 2011/12 2012/13f Market production 10.984 9.651 10.663
More informationWuXi PharmaTech Announces Second-Quarter 2014 Results
WuXi PharmaTech Announces Second-Quarter 2014 Results SHANGHAI, August 13, 2014 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving
More informationCompany results. Company results. Innovative Automatic Machine System Solutions. Innovative Automatic Machine System Solutions INVESTOR RELATIONS
Company results Innovative Automatic Machine System Solutions Company results Innovative Automatic Machine System Solutions Star Conference Milan, March 25 th 2014 1 IMA ata glance Founded in 1961, IMA
More informationBioWales 2015 Pharmaceutical Supply Chain Showcase. 04 March 2015
BioWales 2015 Pharmaceutical Supply Chain Showcase 04 March 2015 SIMBEC RESEARCH 40 YEARS EXPERIENCE IN EARLY STAGE CLINICAL DRUG DEVELOPMENT BACKGROUND Over 1,200 clinical studies safely and successfully
More informationFLOW OF FUNDS REPORT IV TUYID Q1
FLOW OF FUNDS REPORT IV TUYID Q1 2014 January, 2014 Dear Readers, This volume of the Flow of Funds Report, which provides important insight about the inflow and outflow of funds, as well as investment
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationJupiter Fund Management plc. Preliminary Results: 7 March 2012
Jupiter Fund Management plc Preliminary Results: 7 March 2012 Forward-looking statements This presentation may contain certain forward-looking statements with respect to certain plans of Jupiter Fund Management
More informationHealth Care Worldwide
Health Care Worldwide Goldman Sachs - Leveraged Finance Healthcare Conference March 4, 2014 New York Goldman Sachs Leveraged Finance Conference, Fresenius SE & Co. KGaA Copyright, March 4, 2014 Page 1
More informationTo be a global leader in helping customers secure their financial futures
Fulfilling our ambition Alex Wynaendts CEO Analyst and Investor Day, New York City, December 2, 2009 AEGON s ambition To be a global leader in helping customers secure their financial futures o Rebalance
More informationTravis Perkins plc. Financial Results 6 months ended 30 June 2006
Travis Perkins plc Financial Results 6 months ended 30 June 2006 1 Geoff Cooper Chief Executive 2 Highlights Overall market performing in line with expectations Strategy of driving the like for like estate
More information